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Background: Stroke is a major cause of death and disability in the world, and the prevalence of stroke tends to
increase with age. Despite advances in acute care and secondary preventive strategies, primary prevention should
play the most significant role in the reduction of the burden of stroke. As an important component of traditional
Chinese Qigong, Baduanjin exercise is a simple, safe exercise, especially suitable for older adults. However, current
evidence is insufficient to inform the use of Baduanjin exercise in the prevention of stroke.
The aim of this trail is to systematically evaluate the prevention effect of Baduanjin exercise on ischemic stroke in
the community elder population with high risk factors.
Methods: A total of 170 eligible participants from the community elder population will be randomly allocated into
the Baduanjin exercise group and usual physical activity control group in a 1:1 ratio. Besides usual physical activity,
participants in the Baduanjin exercise group will accept a 12-week Baduanjin exercise training with a frequency of
five days a week and 40 minutes a day. Primary and secondary outcomes will be measured at baseline, 13 weeks
(at end of intervention) and 25 weeks (after additional 12-week follow-up period).
Discussion: This study will be the randomized trial to evaluate the effectiveness of Baduanjin exercise for primary
prevention of stroke in community elder population with high risk factors of stroke. The results of this trial will help
to establish the optimal approach for primary prevention of stroke.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-13003588.
Registration date: 24 July, 2013.
Keywords: Baduanjin exercise, Ischemic stroke, Community elder population, Randomized controlled trialBackground
Stroke, about 87% being ischemic [1], causes 9% of all
deaths around the world and is the second most common
single cause of death after ischemic heart disease, with over
five million deaths per year globally [2]. Stroke is also the
most common cause of disability, with 20% of survivors re-
quiring institutional care after three months and 15 to 30%
being permanently disabled [3]. In Europe, it is estimated* Correspondence: lidianchen87@163.com
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unless otherwise stated.about that 250,000 people become disabled after their first
stroke each year [4]. Stroke consumes about 2 to 4% of total
healthcare costs in the world, and accounts for more than
4% of direct healthcare costs in industrialized countries [5].
In China, approximately 1.5 to 2 million new strokes occur
each year, and 15 to 30% of them are permanently disabling
[6]. The economic burden is estimated at a total annual
cost of about ten billion yuan [7]. Although acute treatment
is essential in reducing recurrences and disability, primary
prevention plays the most significant role in the reduction
of the burden of stroke [8]. Therefore, it is important to
make efforts to prevent stroke rather than just treat stroke.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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factors, which can be classified as non-modifiable or
modifiable, have been identified as likely contributors to
its pathogenic progression [9]. The most effective means
available for stroke prevention involve modification and
treatment of risk factors which mainly include high blood
pressure, high cholesterol, high blood glucose, diabetes,
certain other cardiac conditions, dyslipidemia, physical in-
activity, obesity and so on [10-12]. It has been estimated
that over 50% of stroke are preventable through control of
modifiable risk factors [13]. For example, lowering blood
pressure can reduce an approximate 30 to 40% of the risk
of stroke [14,15]; furthermore, 17% further risk reduction
may be obtained by reducing the serum concentration of
LDL-cholesterol [16]. Nevertheless, despite drug therapies
for many of these risk factors being available [17], they re-
main a limitation because of their high costs, unpredictable
side-effects and most subjects having multiple risk factors.
Therefore, this task remains a challenge for societies,
healthcare and financial systems.
The increasing evidence indicates that exercise and
regular physical activity are associated with a reduced
risk of stroke through controlling weight and blood pres-
sure, reducing glucose, and modifying lifestyle [18,19], but
the precise amounts and type of exercise required to pre-
vent stroke still are unclear [20]. Although intensive forms
of physical activity can provide additional protection bene-
fits for stroke, the prevalence of such activities in older
people is quite low [21]. As an important component of
traditional Chinese Qigong exercises, Baduanjin exercise
is an ancient art and science of healthcare that has been
practiced in China for thousands of years [22]. It is a com-
bination of postures, meditation and movements designed
to improve holistic health and to achieve the integration of
mind and body [23-26]. It can exercise the movable joints
and muscle in the whole body, enhancing respiratory func-
tion and at the same time modulating mind and spirit [27].
Many studies have demonstrated the beneficial effects
of Baduanjin exercise on reducing blood lipids [28,29],
lowering blood pressure [30], reducing blood sugar and
glycosylated hemoglobin [31,32]. Recent review has proven
the benefits of Baduanjin exercise on cardiopulmonary
function and body morphology [33]. Additionally, sig-
nificant improvement has been reported in balance,
strength and flexibility, as well as pain reduction and
improvement in sleep quality, psychological well-being
and immune function [34-36]. However, few studies are
randomized trials, most have significant methodological
limitations, and we are not aware of any trials that have
evaluated the impact of Baduanjin exercise on primary
prevention of stroke in the community elder population
with high risk factors for stroke.
This study will adopt the strict randomized controlled
design. The aim is to systematically evaluate the preventiveeffect of Baduanjin exercise on ischemic stroke in the
community elder population with high stroke risk factors
by observing the difference between a Baduanjin exercise
group and a general physical activity group.
Methods/Design
This is a two-arm, randomized, assessor blinded, parallel
controlled trial. The primary aim is to assess the effect
of Baduanjin exercise on risk factors for stroke in the
community elder population.
This trial will be performed at Wufeng Community
Center, in Gulou District, Fuzhou City, China. A total of
170 eligible participants will be randomly allocated into
intervention group (the Baduanjin exercise group) and
control group (general physical activity group) in a 1:1
ratio. The participants in the intervention group will accept
a 12-week Baduanjin exercise training, at the same time
the others in the control group will maintain their original
physical activity. Primary and secondary outcomes will
be measured at baseline, end of 12-week intervention
and after an additional 12-week follow-up period by the
assessors who are not involved in this trial at the Affiliated
Rehabilitation Hospital, Fujian University of Traditional
Chinese Medicine. The statistic analysis will be performed
by a statistician at the Center of Evidence Based Medicine,
Fujian University of Traditional Chinese Medicine. A flow
diagram of this trial is shown in Figure 1.
Sample size
Sample size computation is based on the changes in cere-
bral vascular hemodynamic parameter between comparison
groups with a 5% per comparison significance level and a
two-tailed critical region. The mean and SD of cerebral vas-
cular hemodynamic parameter in the control group as ob-
tained from relevant literature are 32.0 and 6.0 respectively
[37]. We expect a 10% mean improvement of this outcome
after 12-week Baduanjin exercise intervention. A total of
170 participants is calculated as needed to detect the target
effect size with 90% power. In order to avoid excessive loss
to follow-up, we will illustrate in detail to the participants
the potential health benefits of Baduanjin exercise. For
completeness of whole trial progress we will also pro-
vide confidence incentives to participants. Further-
more, we will collect information from participants in
both the Baduanjin exercise and the usual physical ac-
tivity control group regarding the likelihood that they
will drop out. This information will be used to attempt
to reduce the incidence of drop-out.
Participants and recruitment
Eligibility criteria
Definition of people with high risk of ischemic stroke
According to ‘The 2012 annual screening and intervention
project “Workbook of Stroke High Risk Population”’, the
Excluded analysis:n=
Baduanjin exercise group: n=
Usual physical activity group: n=
Included analysis:n=
Baduanjin exercise group: n=
Usual physical activity group: n=
Above outcomes assessment after follow-up period
No eligible (reason):
Not meeting inclusion criteria: n=











Baduanjin exercise group: n=
Usual physical activity grou : n=
Baduanjin exercise group (n =85) Usual physical activity group (n =85)
Complete activity log Receive 12 weeks of Baduanjin exercise 
training and complete activity log 
12 week`s follow-up period Loss to follow-up period (reason): n=
Baduanjin exercise group: n=
Usual physical activity group: n=
Outcomes assessment after intervention: Cerebrovascular function, Cardiopulmonary function, 
Motor function, Physical parameters, Blood lipid, Fasting plasma glucose (FPG) , 
Inflammation factors, Quality of sleep, Quality of life, Happiness, Emotion and mood, 
Self-confidence and self-esteem
Figure 1 Flow diagram of study design.
Zheng et al. Trials 2014, 15:113 Page 3 of 10
http://www.trialsjournal.com/content/15/1/113participants with high risk of ischemic stroke should
meet two of following items (1) to (7) or item (8): (1)
have a history of high blood pressure (systolic/diastolic
pressure ≥ 140/90 mmHg), or be taking antihypertensive
drugs; (2) have atrial fibrillation; (3) smoke (at least one
cigarette each day for one year); (4) have dyslipidemia;
(5) have diabetes mellitus; (6) be obviously overweight
or obese (BMI ≥ 24 kg/m2); (7) have a family history of
stroke (a stroke history in three generations); (8) have
a history of transient ischemic attack (TIA).Inclusion criteria
The eligible participants must meet all the following
criteria: (1) be confirmed as people with high risk of
ischemic stroke; (2) have not conducted regular phys-
ical exercise for at least one year (regular exercise
means lasting more than three months with a fre-
quency of three to four times a week and at least 30
minutes per session); (3) be male or female aged from
50 to 70 years old; (4) have signed the informed consent
document.
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The eligible participants should not meet any of the
following criteria: (1) have a history of stroke; (2) have
been suffering from severe cerebrovascular disease,
musculoskeletal system diseases, or other sports injury
related contraindications; (3) have a communication dis-
order, such as dementia or mental disorder.
Recruitment
The participants’ recruitment will be performed at Wufeng
Community Center in Gulou district, Fuzhou city. We will
recruit the eligible participants through posting-up posters,
sending leaflets, and setting a recruiting station in the
community center. The potentially eligible subjects who
are interested in this study can then contact the recruiters.
The eligible subjects will be included if they are in accord-
ance with the inclusion criteria and not meeting any of the
exclusion criteria.
Randomization and allocation concealment
The eligible participants will be randomly allocated in a 1:1
ratio to either Baduanjin exercise group or the usual phys-
ical activity group. The random allocation sequence will be
generated using the statistical software SAS 9.1 by a statisti-
cian who will be not involve in this trial at the Center of
Evidence Based Medicine, Fujian University of Traditional
Chinese Medicine. The random allocation sequence will be
managed by the project manager who is not involved in the
recruitment program. The eligible participants will be in-
formed of their allocation result by the project manager via
telephone after their baseline information has been assessed.
Blinding
Although it is impossible to blind the participants and exer-
cise coaches due to this being a non-pharmacological inter-
vention trial, two kinds of blind code will be used to blind the
outcome assessors and statistician, and will be kept by a pro-
ject manager who will be involved in the recruitment, inter-
vention, assessment, and statistical analysis procedure of this
trial. The participants’ allocation result (the Baduanjin exer-
cise group or usual physical activity group) will be replaced
by using alphabet ‘A’ or ‘B’ in the first blind code, and the real
meaning of ‘A’ or ‘B’ will be marked in the second blind code.
A twice unclosed blind code will be performed in this
trial. Firstly, after close of data-base, the project manager
will deliver the group code ‘A’ or ‘B’ of participants to
the statistician. Secondly, the project manager will de-
clare the real meaning of group ‘A’ or ‘B’ after analysis
of all data is completed.
Intervention
Baduanjin exercise group
The participants in the Baduanjin exercise group will re-
ceive a 12-week Baduanjin exercise training with afrequency of five days per week and 40 minutes per day.
Eighty-five participants will be freely gathered into three
training units with 25 to 30 people per training unit,
and the Baduanjin exercise training will be performed
at Wufeng Community Center. We will employ three
professional coaches, who have engaged in teaching
the college students physical education at the Fujian
University of Traditional Chinese Medicine for at least
five years, to guide participants’ training. The training
scheme of Baduanjin exercise originated from the
‘Health Qigong Baduanjin Standard’ enacted by the
State Sports General Administration in 2003 [38]. The
whole set of Baduanjin exercise consists of ten pos-
tures (including the preparation and ending posture)
(Figure 2) [39]. Two supervisors will be in charge of
the management of each training site to guarantee the
quality of Baduanjin exercise training.
Usual physical activity group
Participants allocated to the control group will not receive
any specific exercise training from the study scheme.
They will be requested to maintain their original habit
of physical activity.
In order to exclude bias from the exceed activity of
participants, all participants in both groups will be required
to record an activity log in the intervention period, in which
the duration and intensity of their activity or exercise
in a whole day will be classified into three sections in-
cluding the duration of low-intensity activity, the dur-
ation of moderate-intensity activity, and duration of
high-intensity activities.
Follow-up
After the 12-week intervention period, all participants
will enter an additional 12-week unsupervised follow-
up period. They will resume their original lifestyle in
the follow-up period, but they will be required to record
their activity log as in the intervention period. Two super-
visors will investigate the quality of each activity log by
telephone once every two weeks.
Outcome assessment
The outcome assessment will be conducted at baseline
(-2 to -1 weeks), end of intervention (13 weeks), and end
of follow-up period (25 weeks).
The variables in this trial consist of basic characteristic
variables, primary outcomes, and secondary outcomes.
The basic characteristic variables will be measured at
baseline (before randomized allocation); the primary or
second outcomes will be measured at baseline, end of
intervention period, and end of follow-up period, respect-
ively. All outcome assessment will be independently per-
formed by the assessors or operators who are blinded the
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Figure 2 Ten postures of Baduanjin exercise.
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surements in this trial is shown in Table 1.Basic characteristic variables
Demographic characteristics will be collected by the
recruiters through using a standardized questionnaire
(gender, age, nationality, education level, occupation,
marital status).
Information on stroke risk factors regarding smoking,
drinking, height (cm), weight (kg), blood pressure, family
history of stroke, blood lipids, and blood sugar will be
gathered through medical records.
Other information including history of diseases, phys-
ical activity or exercise habits, and drug administrationinformation will be collected by the recruiters through
using a standardized questionnaire.Primary outcomes
Cerebrovascular function consists of cerebral vascular
hemodynamic and cerebrovascular elasticity. Cerebral
vascular hemodynamic parameters consist of the max-
imum blood flow velocity (Vmax), minimum blood flow
velocity (Vmin) and mean blood flow velocity (Vmean).
Those parameters from the vertebral, basilar, middle
cerebral, anterior cerebral and posterior cerebral arterial
territories of the brain will be measured using Color
Doppler ultrasound imaging device (PHILIPS, product
type: IU22) by the professional operators at the Affiliated

















Basic characteristic variables ×
Randomization and allocation concealment ×
Primary outcomes Cerebrovascular function × × ×
Cardiopulmonary function × × ×
Secondary outcomes Motor function × × ×
Physical parameters × × ×
Blood lipids × × ×
Fasting plasma glucose(FPG) × × ×
Inflammation factors × × ×
Quality of sleep × × ×
Quality of life × × ×
Happiness × × ×
Emotion and mood × × ×
Self-confidence and self-esteem × × ×
Adverse events recorded × ×
Activity log × ×
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Chinese Medicine. Cerebrovascular elasticity consists of
the elasticity index (PI) and vascular resistance index (RI)
of vertebral, basilar, middle cerebral, anterior cerebral and
posterior cerebral arteries. It will be measured using Color
Doppler ultrasound imaging device (PHILIPS, product
type: IU22) by the professional operators at the Affiliated
Rehabilitation Hospital of Fujian University of Traditional
Chinese Medicine.
Secondary outcomes
Cardiopulmonary function consists of static lung function
and cardiac function. Static lung function will be mea-
sured using the cardiopulmonary function instruments
(JAEGER, Germany, product type: OXYCON PRO PC) by
the professional operators at the Affiliated Rehabilitation
Hospital of Fujian University of Traditional Chinese
Medicine. Cardiac function will be measured using the
Color Doppler ultrasound imaging device (product type:
SIEMENS Acuson X300) by the professional operators
at the medical examination center of Second People’s
Hospital of Fujian Province.
Motor function includes lumbar and lower limb pro-
prioception function and balance function. Lumbar andlower limb proprioception function will be measured
using the Pro-Kin proprioception evaluation and training
system (produced by Tecnobody S.r.l, Dalmine, Italy,
product type: PK254P) by the professional operators at
the Affiliated Rehabilitation Hospital, Fujian University
of Traditional Chinese Medicine. Balance control will be
measured using the Pro-Kin proprioception evaluation
and training system (produced by Tecnobody S.r.l, Dal-
mine, Italy, product type: PK254P) by the professional
operators at the Affiliated Rehabilitation Hospital, Fujian
University of Traditional Chinese Medicine.
Physical parameters include body mass index (BMI,
weight(kg)/height(m)2), waist-to-hip ratio (waist circum-
ference (cm)/hip circumference (cm)), and flexibility.
BMI will be measured using body scale by the assessors
in this trial. Waist-to-hip ratio will be measured using a
metric rule by the assessors in this trial. Flexibility will
be measured through ‘sit and reach’ test using a ‘sit and
reach’ tester produced by Zhongtitongfang Co., Ltd.,
Beijing, China (product type: CSTF-TQ-5000) by the as-
sessors in this trial.
Blood lipid index consists of serum total cholesterol
(TC), serum triglyceride (TG), low- density lipoprotein
(LDL) and high-density lipoprotein (HDL). They will be
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tion Hospital, Fujian University of Traditional Chinese
Medicine.
Fasting plasma glucose (FPG) will be measured by the
operators at The Affiliated Rehabilitation Hospital, Fu-
jian University of Traditional Chinese Medicine.
Inflammation factors including serum homocysteine
(Hcy), serum c-reactive protein, IL-6, and TNF-α will be
measured using the ELISA method by the assessors at
Center Medical Laboratory, Fujian University of Trad-
itional Chinese Medicine.
Quality of sleep will be measured through use of the
Pittsburgh Sleep Quality Index (PSQI) [40]. The PSQI is
a self-rated questionnaire which assesses sleep quality
within a one month timeframe. Nineteen individual
items generate seven dimensions: subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleeping medication,
and daytime dysfunction [41]. The Chinese version of
PSQI has been reported by Liu Xianchen and his col-
leagues [42] to have acceptable internal consistency,
test-retest reliability, construct validity, and criterion-
related validity.
Quality of life will be measured through use of the
Medical Outcomes Study (MOS) item short form health
survey, SF-36 [43]. The SF-36 scale was constructed to
survey health status in the MOS. The SF-36 includes
one multi-item scale that assesses eight health concepts:
limitation in physical activities because of health prob-
lems; limitations in social activities because of physical
or emotional problems; limitations in usual role activities
because of physical health problems; bodily pain; general
mental health; limitation in usual role activities because of
emotional problems; vitality; and general health perceptions
[44]. The Chinese version of SF-36 has been reported by
Jin Wen-zheng and his colleagues [45] to have reliability
including split-half reliability, internal consistency, criterion
validity and structure validity.
Happiness will be measured by use of the Memorial
University of Newfoundland Scale of Happiness (MUNSH)
[46]. The Chinese version of MUNSH has been reported
by Wang Wen-Xin and his colleagues [47] to have better
effect of re-measure of measuring table, intrinsic correl-
ation by Hotelling’s t-test, better reliability in homogeneity
and better reliability.
Emotion and mood will be measured through use of the
Brief Profile of Mood State (BPOMS) [48]. The BPOMS is
proven to be an excellent measure of affective mood state
fluctuation in a wide variety of populations with a stronger
reliability and validity. Six factors assessed identifiable mood
or affective states include tension-anxiety, vigor-activity,
depression-dejection, fatigue-inertia, anger-hostility, and
confusion-bewilderment [49]. The Chinese version of
BPOMS has been reported by Song Chi and his colleagues[50] to have acceptable internal consistency, construct
validity, and criterion-related validity.
Self-confidence and self-esteem will be measured by use
of the Rosenberg Self-Esteem Scale (RSES) [51]. The RSES
is a self-esteem measure widely used in social-science
research. The ten items, five of the items having positively
worded statements and five having negatively worded
ones, assess the subject’s level of self-esteem by asking
the respondents to reflect on their current feelings
[52]. The Chinese version of RSES has been reported
by Xiangdong Wang and his colleagues [53] to have
acceptable internal consistency, construct validity, and
criterion-related validity.
Safety
Although no adverse event from Baduanjin exercise is
reported to this day, all unexpected adverse events during
the intervention period will be reported to the project man-
ager, and the causality with Baduanjin exercise intervention
will be analyzed. If serious adverse events do occur, they
will be reported to the primary researchers and ethics
committee immediately and they will decide whether
the participant needs to withdraw from this trial.
Statistical analysis
Statistical analyses will be performed using SPSS 21.0
(IBM, Chicago, IL, USA) software packages by a statistician,
who is not involved in the outcome measurements, at
Center of Evidence Based medicine, Fujian University
of Traditional Chinese Medicine. The statistical signifi-
cance is defined as two-sided P value of < 0.05. In de-
scriptive analysis of the sample, the central tendency
for the continuous variables will be expressed using
mean (standard deviation) or median (interquartile range)
for symmetrical distributions; normality will be tested using
the Kolmogorov-Smirnov test. Appropriate transformations
will be applied in cases of a non-normal distribution. The
categorical variables will be expressed as proportions with
their standard error. Statistical comparisons for the baseline
characteristics, primary and secondary outcomes between
groups will be compared using the Student’s t-test or
Mann-Whitney U-test for continuous variables and the
Pearson Chi-squared or Fisher exact test for categorical var-
iables. Analysis of the primary and secondary outcomes will
be on the basis of the intention-to-treat (ITT) population
and per-protocol (PP) population. The result of the ITT
analysis will be compared with that of the PP analysis to de-
termine whether the results are consistent. Every effort will
be made to minimize missing data and drop-out or loss to
follow-up during the study period. Missing data will be
filled by Bayesian methods. If the amount of missing data
for primary outcome or potential confounders is substantial
(that is > 10%), multiple imputation methods will be con-
sidered to perform the statistic analysis. Linear models or
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variables and logistic regression models for dependent
categorical variables if incomparability of baseline char-
acteristics between groups appears. Subgroup analysis
stratified by participants’ sex will be used for the pri-
mary outcomes. Analysis of variance (ANOVA) will be
used for the repeated measurement data, and the post
hoc comparison will be applied if the difference is found
to be significant. Adverse events will be listed and ana-
lyzed using a Chi-squared or Fisher’s exact test. Severe
adverse events will be listed in detail.
Ethics
This protocol is in accordance with the Declaration of
Helsinki. The study protocol and consent forms were
approval by Medical Ethics Committee of the Affiliated
People's Hospital, Fujian University of Traditional Chinese
Medicine (approval number: 2013-021-02). Participants will
sign the informed consent document prior to participation.
Dissemination policy
Study protocol has been registered, and is available on
the Chinese Trial Registry website (Registered in ChiCTR.
org with the identifier ChiCTR-TRC-13003588). All partici-
pants will be the first to be informed of trail results. They
will then be published in scientific journals if possible
regardless of the magnitude or direction of effect. No
professional writers will be employed.
Discussion
Baduanjin exercise is a traditional Chinese Qigong which
is characterized by simple, slow, relaxing movements. It
has been practiced as a popular and safe community ex-
ercise to promote health for hundreds years in China
[54]. Baduanjin exercise involves eight sections of move-
ment, each of which benefits different parts of the body
[38]. Previous studies have indicated that Baduanjin ex-
ercise can improve blood lipid metabolism, insulin sensi-
tivity, and blood pressure for community older adults
[29-31]. However, few studies are randomized trials and
most have significant methodological limitations [32,36].
Current evidence therefore, is insufficient to inform the
use of Baduanjin exercise in the prevention of stroke.
The primary purpose of this trial was to systematically
assess the effectiveness of regular Baduanjin exercise on
primary prevention of stroke in community elder popu-
lation through detection of improvement in cerebrovas-
cular function, cardiopulmonary function, and exposure
of risk factors for stroke compared with people with
usual physical activities. This trial will employ adequate
methods to reduce bias, such as randomization, blinding
to the outcome assessors and statistical analyzers, a large
subject population and analysis according to the intent-
to-treat (ITT) principle. It is expected that Baduanjinexercise will have an obvious positive effect on primary
prevention of ischemic stroke in the community elder
population with high risk factors.
This trial has potential limitations. In the ideal situ-
ation, everyone involved in a randomized controlled
trial should be blinded but this is not always feasible in
non-pharmacological trials [55]. Although the partici-
pants and exercise coaches will be not blinded in this
trial, the outcome assessors and statistical analyzers
will be blinded concerning information about treat-
ment allocation. In the intervention period, all partici-
pants in both groups will be required to record their
activity log, which includes the duration and intensity
of their activity or exercise in a whole day. In the process
of outcomes assessment, the participants will be asked not
to reveal their treatment group to assessors. The whole
intervention of Baduanjin exercise in the treatment group
will be performed in an outdoor setting, so occasional
intervention interruption may therefore be unavoid-
able due to adverse weather. In this does occur, we will
ask participants in the treatment group to perform self-
practice at home.
In summary, this study will be the first randomized
trial to evaluate the impact of Baduanjin exercise on
primary prevention of stroke in a community elder
population with high risk factor of stroke. The results
of this trial will help to establish the optimal approach
for preventing stroke in high risk groups and provide
reliable evidence for its application in the rehabilitation of
Traditional Chinese Medicine.Trial status
Recruitment started while the manuscript was being
finished.
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